Safe and Effective Permeation Enhancers for Oral Drug Delivery

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2007 Dec 7

PMID 18058001

Citations 34

Authors

Kathryn Whitehead

Natalie Karr

Samir Mitragotri

Affiliations

Soon will be listed here.

Abstract

Purpose: The use of intestinal permeation enhancers to overcome the absorption challenges associated with oral drug delivery has been hampered by the notion that enhancer efficacy is directly linked to toxicity. This study attempts to gain insight into the principles governing the potency and toxicity behavior of enhancers.

Methods: Fifty-one enhancers were selected from 11 chemical categories and their potency and toxicity were analyzed in Caco-2 monolayers at concentrations spanning three orders of magnitude.

Results: A small but significant fraction of the 153 enhancer formulations studied demonstrated unexpected but desired behavior, that is, substantial efficacy without marked toxicity. Our results revealed that both chemical category and concentration proved critical in determining the usefulness of many enhancers, and the concept of an enhancer's 'therapeutic window' is discussed. Several of the most promising enhancers identified by the study were tested for their effect on the transport of the marker molecules mannitol and 70 kDa dextran across Caco-2 cells and were capable of increasing permeability more than 10-fold.

Conclusions: The results presented here underscore the potential of chemical permeation enhancers while providing valuable direction as to what classes and concentrations of compounds are of interest when searching for safe and effective additions to oral formulations.

Citing Articles

Maternal milk cell components are uptaken by infant liver macrophages via extracellular vesicle mediated transport.

Doerfler R, Yerneni S, LoPresti S, Chaudhary N, Newby A, Melamed J FASEB J. 2025; 39(2):e70340.

PMID: 39835705 PMC: 11748825. DOI: 10.1096/fj.202402365R.

Mucosal Penetrative Polymeric Micelle Formulations for Insulin Delivery to the Respiratory Tract.

Kang J, Jeong J, Kwon Y, Kim Y, Shin D, Park Y Int J Nanomedicine. 2024; 19:9195-9211.

PMID: 39267725 PMC: 11390838. DOI: 10.2147/IJN.S474287.

A new crystalline daidzein-piperazine salt with enhanced solubility, permeability, and bioavailability.

Meng J, Qiu C, Lu C, He X, Zhao X Front Pharmacol. 2024; 15:1385637.

PMID: 39104399 PMC: 11298695. DOI: 10.3389/fphar.2024.1385637.

Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery.

Ramirez-Velez I, Belardi B Adv Drug Deliv Rev. 2023; 199:114905.

PMID: 37271282 PMC: 10999255. DOI: 10.1016/j.addr.2023.114905.

Long-term daily oral administration of intestinal permeation enhancers is safe and effective in mice.

Fein K, Gleeson J, Cochran K, Lamson N, Doerfler R, Melamed J Bioeng Transl Med. 2023; 8(1):e10342.

PMID: 36684095 PMC: 9842030. DOI: 10.1002/btm2.10342.

References

Mustata G, Dinh S . Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst. 2006; 23(2):111-35. DOI: 10.1615/critrevtherdrugcarriersyst.v23.i2.20. View

Warrington J, von Moltke L, Harmatz J, Shader R, Greenblatt D . The effect of age on sildenafil biotransformation in rat and mouse liver microsomes. Drug Metab Dispos. 2003; 31(11):1306-9. DOI: 10.1124/dmd.31.11.1306. View

Shah R, Palamakula A, Khan M . Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. J Pharm Sci. 2004; 93(4):1070-82. DOI: 10.1002/jps.20007. View

Whitehead K, Shen Z, Mitragotri S . Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release. 2004; 98(1):37-45. DOI: 10.1016/j.jconrel.2004.04.013. View

Aungst B . Intestinal permeation enhancers. J Pharm Sci. 2000; 89(4):429-42. DOI: 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J. View

Tao S, Desai T . Gastrointestinal patch systems for oral drug delivery. Drug Discov Today. 2005; 10(13):909-15. DOI: 10.1016/S1359-6446(05)03489-6. View

Konsoula R, Barile F . Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro. 2005; 19(5):675-84. DOI: 10.1016/j.tiv.2005.03.006. View

Lindmark T, Kimura Y, Artursson P . Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther. 1998; 284(1):362-9. View

Salama N, Eddington N, Fasano A . Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev. 2006; 58(1):15-28. DOI: 10.1016/j.addr.2006.01.003. View

10.

NICOLAY F, Harder A, von Samson-Himmelstjerna G, Mehlhorn H . Synergistic action of a cyclic depsipeptide and piperazine on nematodes. Parasitol Res. 2001; 86(12):982-92. DOI: 10.1007/pl00008530. View

11.

Swenson E, Milisen W, Curatolo W . Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res. 1994; 11(8):1132-42. DOI: 10.1023/a:1018984731584. View

12.

Duizer E, van der Wulp C, Versantvoort C, Groten J . Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells. J Pharmacol Exp Ther. 1998; 287(1):395-402. View

13.

Fuller E, Duckham C, Wood E . Disruption of epithelial tight junctions by yeast enhances the paracellular delivery of a model protein. Pharm Res. 2006; 24(1):37-47. DOI: 10.1007/s11095-006-9124-0. View

14.

Radwant M, Aboul-Enein H . The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul. 2002; 19(2):225-35. DOI: 10.1080/02652040110081406. View

15.

Lindhardt K, Bechgaard E . Sodium glycocholate transport across Caco-2 cell monolayers, and the enhancement of mannitol transport relative to transepithelial electrical resistance. Int J Pharm. 2003; 252(1-2):181-6. DOI: 10.1016/s0378-5173(02)00629-4. View

16.

Karande P, Jain A, Mitragotri S . Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J Control Release. 2005; 110(2):307-313. DOI: 10.1016/j.jconrel.2005.10.012. View

17.

Fray M, Bish G, Fish P, Stobie A, Wakenhut F, Whitlock G . Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006; 16(16):4349-53. DOI: 10.1016/j.bmcl.2006.05.049. View

18.

Serra L, Domenech J, Peppas N . Drug transport mechanisms and release kinetics from molecularly designed poly(acrylic acid-g-ethylene glycol) hydrogels. Biomaterials. 2006; 27(31):5440-51. DOI: 10.1016/j.biomaterials.2006.06.011. View

19.

Goldberg M, Gomez-Orellana I . Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003; 2(4):289-95. DOI: 10.1038/nrd1067. View

20.

Takatsuka S, Kitazawa T, Morita T, Horikiri Y, Yoshino H . Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur J Pharm Biopharm. 2005; 62(1):52-8. DOI: 10.1016/j.ejpb.2005.07.008. View